NCT07172347View on ClinicalTrials.gov

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions
Non-segmental Vitiligo
Interventions
DRUG

VC005 tablets

VC005 groups repeat administration for 52 weeks

DRUG

VC005 Tablets Placebo

VC005 Placebo groups repeat administration for 52 weeks

Trial Locations (1)

Unknown

The Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY